Added to YB: 2026-03-25
Pitch date: 2026-03-23
NAUT [bullish]
Nautilus Biotechnology, Inc.
+6.47%
current return
Author Info
Company Info
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States.
Market Cap
$383.5M
Pitch Price
$3.71
Price Target
N/A
Dividend
N/A
EV/EBITDA
-5.70
P/E
-6.48
EV/Sales
N/A
Sector
Life Sciences Tools and Services
Category
growth
Nautilus Biotechnology: A Digital Twin of Your Proteome.
NAUT: Pre-revenue proteomics co developing iterative mapping platform to digitize proteome at proteoform level, surpassing mass spec's fragmentation limits. 3+ orders magnitude dynamic range vs 1 industry avg. Q4'25 launched tau assay early access; expanding into Parkinson's via 18mo Michael J. Fox collab on alpha-synuclein. Oncology assay targeting H2'26. $103M cash, burn improved from $81.5M (2024) to $66.8M (2025), $30M debt flat. $380M mcap. Platform hard to replicate due to fluorescent tag binding kinetics complexity. Long-term thesis: population-wide real-time proteome digital twin for AI-driven disease prevention. Risk: unproven commercial viability, capital intensive R&D.
Read full article (5 min)